News about Clinical Trials

Clover Biopharmaceuticals Completes Initial Enrollment in Phase II Trial of RSV Combination Vaccines

The Australia-based Phase II study is evaluating Clover’s protein-based combination vaccine candidates SCB-1022 and SCB-1033 targeting RSV, hMPV and PIV3 in older adults, using its proprietary Trimer-Tag technology.

Clinical Trials | 12/01/2026 | By News Bureau |  579

Pfizer Reports Improved Response Rates with BRAFTOVI Regimen in Metastatic Colorectal Cancer

New data from the BREAKWATER study show that Pfizer’s BRAFTOVI-based regimen significantly improved response rates in patients with BRAF V600E–mutant metastatic colorectal cancer, supporting the potential use of flexible chemotherapy backbones.

Clinical Trials | 12/01/2026 | By News Bureau |  149

Remedy Cell Launches Phase 1b Trial of RC-0315 in IPF

First-in-human study evaluates safety and tolerability of intra-bronchial RC-0315, a cell-derived therapy aimed at reducing fibrosis and restoring lung function in idiopathic pulmonary fibrosis patients.

Clinical Trials | 08/01/2026 | By News Bureau |  196

Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer

Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.

Clinical Trials | 08/01/2026 | By News Bureau |  307

Acesion Pharma Begins Phase-II Trial of AP31969 in Atrial Fibrillation

The Phase-II study of AP31969 by Acesion Pharma will evaluate the efficacy and safety of AP31969, a first-in-class oral SK ion channel inhibitor, in reducing atrial fibrillation burden using continuous cardiac rhythm monitoring.

Clinical Trials | 08/01/2026 | By News Bureau |  184

China Updates Ivonescimab Label After NSCLC Survival Gains

China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />

Clinical Trials | 07/01/2026 | By News Bureau |  483

HUTCHMED Begins Phase III Trial of Surufatinib-Camrelizumab Combo in Pancreatic Cancer

HUTCHMED has initiated the phase-III stage of its phase-II/III clinical trial in China evaluating a combination regimen of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, with the first patient dosed on 30 December, 2025.

Clinical Trials | 05/01/2026 | By News Bureau |  210

FibroBiologics Files IND Application with US FDA for CYPS317 in Psoriasis

FibroBiologics has filed an Investigational New Drug (IND) application with the US FDA for CYPS317, marking a key step towards initiating clinical development of the therapy for psoriasis, supported by encouraging preclinical data showing reduced disease severity and relapse.

Clinical Trials | 03/01/2026 | By News Bureau |  194

XORTX Unveils New Research on Genome-Wide Pathways in Gout

XORTX Therapeutics highlighted findings from recent independent, peer-reviewed research showing that multiple genetic factors are linked to over-expression of Xanthine Oxidase (XO), chronically elevated blood uric acid levels, and gout—further reinforcing the company’s strategy of targeting XO to treat gout, kidney, and related diseases.

Clinical Trials | 01/01/2026 | By News Bureau |  109

Senhwa Expands Oncology Manufacturing Focus With CX-5461 - ADC Combination Trial

Senhwa Biosciences, Inc. has announced a significant clinical development milestone with its first-in-class investigational agent Pidnarulex (CX-5461) set to be evaluated in combination with the antibody–drug conjugate trastuzumab deruxtecan (Enhertu) in a phase 1b clinical trial.

Clinical Trials | 30/12/2025 | By Darshana |  159